key: cord-1019332-xrpibea3 authors: Chauhan, L.; Pattee, J.; Ford, J.; Thomas, C.; Lesteberg, K.; Richards, E.; Loi, M.; Dumont, L. J.; Annen, K.; Berg, M.; Zirbes, M.; Miller, A.; Jenkins, T. C.; Bennett, T. D.; Monkowski, D.; Boxer, R. S.; Beckham, J. D. title: A Multi-center, Prospective, Observational-cohort controlled study of Clinical Outcomes following COVID-19 Convalescent plasma therapy in hospitalized COVID-19 patients date: 2021-06-18 journal: nan DOI: 10.1101/2021.06.14.21258910 sha: ee409286ee768a8116949bc495d816a0f342d524 doc_id: 1019332 cord_uid: xrpibea3 Background: The SARS-CoV2 pandemic has caused high inpatient mortality and morbidity throughout the world. COVID19 convalescent plasma has been utilized as a potential therapy for patients hospitalized with COVID19 pneumonia. This study evaluated the outcomes of hospitalized COVID19 patients treated with COVID19 convalescent plasma in a prospective, observational multicenter trial. Methods: From April 2020 through August 2020, hospitalized COVID19 patients at 16 participating hospitals in Colorado were enrolled and treated with COVID19 convalescent plasma (CCP) and compared to hospitalized patients with COVID19 who were not treated with convalescent plasma. Plasma antibody levels were determined following the trial given that antibody tests were not approved at the initiation of the trial. CCP-treated and untreated COVID19 hospitalized patients were matched using propensity scores followed by analysis for length of hospitalization and inpatient mortality. Results: 542 total hospitalized COVID19 patients were enrolled at 16 hospitals across the region. A total of 468 hospitalized COVID19 patients were entered into propensity score matching with 188 patients matched for analysis in the CCP-treatment and control arms. Fine-Gray models revealed increased length of hospital stay in CCP-treated patients and no change in inpatient mortality compared to controls. In subgroup analysis of CCP-treated patients within 7 days of admission, there was no difference in length of hospitalization and inpatient mortality. Conclusions: These data show that treatment of hospitalized COVID19 patients with CCP did not significantly improve patient hospitalization length of stay or inpatient mortality. arms. Fine-Gray models revealed increased length of hospital stay in CCP-treated 55 patients and no change in inpatient mortality compared to controls. In subgroup analysis 56 of CCP-treated patients within 7 days of admission, there was no difference in length of 57 hospitalization and inpatient mortality. . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted June 18, 2021. ; https://doi.org/10.1101 https://doi.org/10. /2021 Convalescent plasma, hyper-immune globulin, and monoclonal antibodies are 77 different passive antibody therapeutics evaluated as possible treatments for Recent studies of COVID19 convalescent plasma (CCP) therapy in several studies 79 have shown potential benefit of treatment in hospitalized COVID19 patients. [4] [5] [6] [7] contra-indication to receiving plasma products, and risk of transfusion exceeds potential 117 benefit based on clinician determination. Control patients were identified, and data captured over each month of the study 119 using a UCHealth database of hospitalized COVID19 patients for each month from April 120 through August of 2020. Data was abstracted from all hospitalized COVID-19 patients in 121 the UCHealth system that met the inclusion and exclusion criteria above but did not 122 . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted June 18, 2021. ; https://doi.org/10.1101/2021.06.14.21258910 doi: medRxiv preprint receive CCP therapy over the same time period. As previously described, all patient CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted June 18, 2021. ; https://doi.org/10.1101/2021.06.14.21258910 doi: medRxiv preprint Propensity score matching was performed to ensure that potential confounding 145 factors were balanced between the CCP treatment group and the control group. Propensity score matching is an analysis approach utilized for non-randomized trials to CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted June 18, 2021. ; https://doi.org/10.1101/2021.06.14.21258910 doi: medRxiv preprint We modeled the primary outcome (time to hospital discharge) in a competing 167 risks framework, where in-hospital mortality is considered to be a competing risk. [18] All 168 study subjects were observed until time to in-hospital mortality or discharge, thus there 169 was no censoring. There were a small number of patients who were discharged from 170 the hospital, and later returned to the hospital and experienced in hospital mortality. The 171 analysis treated the eventual in-hospital mortality for these patients as unobserved. In the Fine-Gray models, time to event is regressed on an indicator variable denoting 176 treatment status with no other covariates. 178 In our primary intention to treat analysis, 188 treatment and control subjects were 179 retained after propensity score matching for 376 total patients included in the trial 180 (Figure 1) . The variance ratio was used to assess covariate variance balance, with 181 balance defined to be a variance ratio < 2. [19] Covariate balance was achieved after 182 propensity score matching for the intention to treat analysis (Figure 2) . Propensity score 183 matching was also performed for the sub-analyses that limited the study population 184 based on time to infusion. Covariate balance was achieved for the 7 or fewer days to 185 infusion analysis and was nearly, but not achieved for the 3 or fewer days to infusion 186 analysis (Supplementary Figures 1&2) . Subject characteristics for the propensity 187 score matched intention to treat analysis are displayed in Table 1 . Overall, the cohorts 188 enrolled represented the regional outbreak with higher proportion of older adult patients 189 . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted June 18, 2021. to control) on hospital discharge and inpatient mortality ( Table 2) . As these coefficients 212 . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted June 18, 2021. ; https://doi.org/10.1101/2021.06.14.21258910 doi: medRxiv preprint were estimated via Fine-Gray models, they should be interpreted as changes in the 213 sub-distribution hazard function for each event type. [20] Values less than one indicate 214 that treatment status reduces the hazard of the corresponding event. The estimated 215 Aalen-Johansen incidence curves for hospital discharge and in-hospital mortality for 216 each matched cohort show the probability of hospital discharge or inpatient mortality 217 over time (Figure 3) . 218 Analysis of COVID19 patients that received CCP treatment within 7 or 3 days of 219 admission revealed no significant difference in hospital discharge or inpatient mortality 220 in CCP treated patients compared to control patients ( Table 2 ). The Aalen-Johansen 221 curves for CCP-treated patients within 7 or 3 days of admission also show no significant 222 difference in hospital discharge or inpatient mortality when compared to control 223 COVID19 patients (Supplementary Figures 3-6) . 224 Four patients had documented adverse events associated with CCP infusion. Three patients had allergic reactions with pruritus, rash, or urticaria, which resolved In this prospective, open-label, multicenter cohort-controlled study, we found that 232 treatment of hospitalized COVID19 patients with CCP did not significantly improve time 233 to hospital discharge or inpatient mortality compared to propensity matched controls. . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted June 18, 2021. ; https://doi.org/10.1101/2021.06.14.21258910 doi: medRxiv preprint Given that hospital discharge is considered a positive endpoint, the fact that treatment 235 reduces the hazard of hospital discharge is evidence that CCP treatment may have a 236 negative effect on the prognosis of study participants. However, this statistically 237 significant effect disappears in the two sub-analyses. This may be because study 238 participants who received convalescent plasma more than 7 days after hospital 239 admission differ systematically from the rest of the study population. For example, the 240 patients that received CCP after 7 days may bias the treatment group to more severe 241 disease. We also found that CCP treatment status does not have a statistically 242 significant effect on the hazard of inpatient mortality. It would be difficult to detect an 243 effect of convalescent plasma treatment on the hazard of inpatient mortality in this study 244 given the relatively few number of inpatient deaths. CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted June 18, 2021. ; https://doi.org/10.1101/2021.06.14.21258910 doi: medRxiv preprint relative risk for death as compared to patients in low titer group. However, this study did Similar to prior studies, we found that convalescent plasma transfusion was well 277 tolerated with rare adverse events. [22, 25, 26] In our study, we did not document any 278 major transfusion reactions including transfusion-associated acute lung injury or 279 . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The risks of CCP-treatment in hospitalized COVID19 patients are minimal, this study 297 shows that treatment with CCP for hospitalized COVID19 patients provides no 298 significant improvement in length of hospitalization or inpatient mortality. Ongoing 299 multicenter, randomized controlled trials of CCP treatment for hospitalized and 300 . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted June 18, 2021. ; https://doi.org/10.1101 https://doi.org/10. /2021 outpatient COVID19 patients are critical to define a potential role for CCP therapy in the 301 SARS-CoV-2 epidemic. . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) The copyright holder for this preprint this version posted June 18, 2021. ; https://doi.org/10.1101/2021.06.14.21258910 doi: medRxiv preprint CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) The copyright holder for this preprint this version posted June 18, 2021. ; https://doi.org/10.1101/2021.06.14.21258910 doi: medRxiv preprint CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) The copyright holder for this preprint this version posted June 18, 2021. ; https://doi.org/10.1101/2021.06.14.21258910 doi: medRxiv preprint Effect of Convalescent Plasma Therapy on Time to Clinical Improvement in Patients With 342 Severe and Life-threatening COVID-19: A Randomized Clinical Trial A Randomized Trial of Convalescent Plasma in Covid-19 Severe Pneumonia Research electronic data 352 capture (REDCap)--a metadata-driven methodology and workflow process for providing 353 translational research informatics support Propensity score methods Early predictors of clinical outcomes of COVID-362 Matching methods for causal inference: A review and a look forward Optimal caliper widths for propensity-score matching when estimating differences 366 in means and differences in proportions in observational studies Balance 369 diagnostics after propensity score matching How to handle mortality when investigating 371 length of hospital stay and time to clinical stability Balance diagnostics for comparing the distribution of baseline covariates between 373 treatment groups in propensity-score matched samples Practical recommendations for reporting Fine-Gray model analyses for 375 competing risk data Effect of Convalescent Plasma Therapy on Time to Clinical Improvement in Patients With 380 Severe and Life-threatening COVID-19: A Randomized Clinical Trial Early High-Titer Plasma Therapy to Prevent Severe Covid-19 in Older Adults. 391 Convalescent plasma in the management of moderate covid-19 in adults in India: open 394 label phase II multicentre randomised controlled trial (PLACID Trial) 400 A., Convalescent Plasma for COVID-19. A randomized clinical trial 408 Safety Update: COVID-19 Convalescent Plasma in 20,000 Hospitalized Patients Early safety indicators of COVID-19 convalescent plasma in 5000 416 patients